Latest News
Omeros Finalises with FDA Clinical Plan for OMS721 Approval in IgA Nephropathy
18 January 2019 - - US-based commercial-stage biopharmaceutical company Omeros Corp. (NASDAQ: OMER) has finalised its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy following a recent meeting with the US Food and Dru...
Aerpio Pharmaceuticals Completes Patient Dosing in TIME-2b Study of AKB-9778 in Diabetic Retinopathy
18 January 2019 - - US-based biopharmaceutical company Aerpio Pharmaceuticals, Inc. (NASDAQ: ARPO) has completed patient dosing in the company's TIME-2b study, a Phase 2b clinical trial designed to assess the efficacy and safety of Aerpio's...
vTv Therapeutics Publishes Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study
18 January 2019 - - A new paper in Science Translational Medicine showcases the discovery and development of TTP399, an investigational, oral, small molecule, liver-selective glucokinase activator, as a potential treatment for diabetes, the...
Qiagen Receives Approval for EGFR Test in Lung Cancer as Companion Diagnostic in Japan
18 January 2019 - - The Japanese Pharmaceuticals and Medical Device Agency has approved the therascreen EGFR RGQ PCR Kit to allow its use as a companion diagnostic with Pfizer's Vizimpro (dacomitinib) for EGFR gene mutation-positive, i...
Spectrum Pharmaceuticals reports divestiture of marketed portfolio to focus on new and innovative therapies for cancer patients
18 January 2019 - Biotechnology company Spectrum Pharmaceuticals Inc (NASDAQ-GS:SPPI) revealed on Thursday the launch of a definitive agreement to divest its portfolio of seven products to Acrotech Biopharma LLC, a New Jersey-based wholly-owned subsi...